Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET

Company Participants

Richard Lepke - Senior Director, Investor Relations
Marianne De Backer - Chief Executive Officer
Jennifer Towne - Executive Vice President and Chief Scientific Officer
Mark Eisner - Executive Vice President and Chief Medical Officer
Brent Sabatini - Chief Accounting Officer

Conference Call Participants

Phil Nadeau - TD Cowen
Nikola Gasic - Leerink
Paul Choi - Goldman Sachs
Eric Joseph - J.P. Morgan
Mike Ulz - Morgan Stanley
Joseph Stringer - Needham & Company
Alec Stranahan - Bank of America

Operator

Hello. Welcome to Vir Biotechnology’s Second Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]

I will now turn the call over to Richard Lepke, Senior Director of Investor Relations. You may begin Mr. Lepke.

Richard Lepke

Thank you, operator and hello everyone. I am Richard Lepke, Senior Director of Investor Relations at Vir Biotechnology. Joining me on the call are Dr. Marianne De Backer, our Chief Executive Officer; Dr. Jennifer Towne, our Chief Scientific Officer; Dr. Mark Eisner, our Chief Medical Officer; and Brent Sabatini, our Chief Accounting Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements, to differ significantly from those expressed or implied by such forward looking statements. These risks and uncertainties and risks associated with our business are described in today's press releases and the company's reports filed with the Securities and Exchange Commission, including Forms 10-K, 10-Q and 8-K.

With that, I will turn the call over to Marianne. Please go ahead.

Marianne De Backer

Good afternoon, everyone, and thank you for joining us today. At Vir, our mission is powering the immune system to transform lives. During today's earnings call, we will discuss two significant announcements that mark critical milestones on our journey to realize this vision.

Before we dive into these announcements, let me quickly highlight some key achievements from the second quarter. We presented promising Phase 2 SOLSTICE data in chronic hepatitis delta at the EASL Congress, which generated significant interest from both scientific as well as the medical community. These preliminary data underscore the potential of our combination therapy to tobevibart and elebsiran to revolutionize the treatment landscape for people living with hepatitis delta. We are now preparing to engage with regulatory authorities to discuss the registrational path forward. We also recently received FDA IND clearance and fast track designation for this combination therapy.